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OBJECTIVES: Antineutrophil cyto plasmic antibody-associated vasculitis (AAV) is a fatal disease. Currently,
predictors of mortality due to AAV are based on the distribution of organ involvement. The novel fibrosis index
(NFI) is an index composed of laboratory results that reflect the degree of liver fibrosis. This study aimed to
evaluate whether NFI can predict poor outcomes in patients with AAV without substantial liver disease.
METHODS: A total of 210 patients with immunosuppressive drug-naı̈ve AAV were retrospectively reviewed. NFI
was calculated as follows: NFI=(serum bilirubin  (alkaline phosphatase)2)/(platelet count (serum albumin)2).
NFI cut-off was set at 1.24 (the highest quartile). Poor outcomes were defined as all-cause mortality, relapse, and
end-stage renal disease (ESRD).
RESULTS: During the median 34.5 months of follow-up, 21 patients (10%) died, 72 patients (34.3%) relapsed,
and 38 patients (18.1%) had ESRD due to AAV progression. The median calculated NFI was 0.61, and it was
higher in AAV patients with all-cause mortality than in those without mortality, but the difference was not
statistically significant (1.26 vs. 0.59). AAV patients with NFI at diagnosis X1.24 exhibited a significantly lower
cumulative patient survival rate than those with NFI at diagnosis o1.24 (p=0.002). Multivariate Cox hazard
model analysis showed that NFI at diagnosis X1.24 was an independent predictor of all-cause mortality in AAV
(hazard ratios [HR] 2.850, 95% confidence interval [CI] 1.026, 7.910).
CONCLUSIONS: NFI X1.24, which may be an independent predictive marker for all-cause mortality in AAV
patients without substantial liver disease.
KEYWORDS: Antineutrophil Cytoplasmic Antibody-Associated Vasculitis; Novel Fibrosis Index; Predict; All-Cause
Mortality.
’ INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a systemic vasculitis characterized by
necrotizing vasculitis in small-sized vessels, arterioles, venu-
les, capillaries, and, occasionally, arteries. AAV has three
subtypes based on histological and clinical features: micro-
scopic polyangiitis (MPA), granulomatosis with polyangiitis
(GPA), and eosinophilic granulomatosis with polyangiitis
(EGPA) (1). Various classification criteria and definitions
have been suggested, including the 2007 European Medicine
Agencies algorithm for AAV and the 2012 revised Interna-
tional Chapel Hill Consensus Conference (CHCC) Nomen-
clature of Vasculitides, widely used to diagnose AAV (1,2).
The disease activity of AAV is assessed and expressed by the
Birmingham vasculitis activity score (BVAS), which consists
of nine items (3). In addition, the vasculitis damage index
(VDI) is used to assess the irreversible damage caused by
AAV, and a five-factor score (FFS) is used to predict prog-
nosis (4,5).
BVAS or VDI include several major organs, but they do not
contain the symptoms or damages of liver involvement in
AAV. Similarly, a previous study reported that the progres-
sion of liver involvement or autoimmune hepatitis was rarely
observed in patients with AAV (6). Meanwhile, another
earlier study reported that liver fibrosis indices wereDOI: 10.6061/clinics/2021/e2501
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associated with all-cause mortality in patients with AAV
without substantial chronic liver disease (7). Concerning
AAV, a hypothesis is more persuasive that these results
might have been related to the variables’ association of the
variables. These variables comprise the liver fibrosis indices
formulas, with the cross-sectional inflammatory burden and
its related poor outcomes of AAV, rather than the direct asso-
ciation between the liver fibrosis indices and liver involve-
ment of AAV.
Recently, two similar liver fibrosis indices have been
introduced: fibrosis cirrhosis index (FCI) and novel fibrosis
index (NFI). Both FCI and NFI are newly designed indicators
to predict the degree of liver fibrosis non-invasively. FCI is
calculated by a formula consisting of four parameters: FCI=
(serum bilirubin alkaline phosphatase)/(platelet count
serum albumin) (8). NFI is a modified formula by squaring
both alkaline phosphatase in the molecule of FCI and serum
albumin in the denominator of the formula FCI: NFI=(serum
bilirubin (alkaline phosphatase)2)/(platelet count (serum
albumin)2) (9).
NFI is a modified formula by squaring both alkaline
phosphatase in the FCI molecule and serum albumin in the
FCI formula denominator. NFI amplifies the reflected contri-
bution of alkaline phosphatase, which shows a positive corre-
lation with liver fibrosis, and serum albumin, which shows a
negative correlation (9). Among the NFI variables, few pre-
vious reports on the association of AAV prognosis with
bilirubin or alkaline phosphatase at diagnosis. Still, the asso-
ciation of AAV prognosis and either platelet count or serum
albumin at diagnosis has already been demonstrated (10,11).
Therefore, it can be speculated that NFI at diagnosis could
predict poor outcomes of AAV during follow-up. However,
there has been no report on the clinical significance of NFI at
diagnosis in the disease course of AAV. Hence, in this study,
we investigated whether NFI at diagnosis might be associated
with AVV’s cross-sectional activity and could predict the
poor outcomes of AAV, particularly all-cause mortality, during
follow-up in immunosuppressive drug-naïve patients with
AAV without substantial chronic liver disease.
’ MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of 210
immunosuppressive drug-naïve AAV patients, who had
been classified as AAV based on the 2007 EMA algorithm
and the 2012 CHCC definitions at the Division of Rheuma-
tology, Department of Internal Medicine, Yonsei University
College of Medicine, Severance Hospital between October
2000 and March 2020 (1,2). BVAS and FFS were collected,
and if not available, they were calculated based on clinical
and laboratory data documented in the medical records.
Confirmation of ANCA, both by an indirect immuno-
fluorescence assay (IFA) for perinuclear (P)-ANCA and
cytoplasmic (C)-ANCA and antigen-specific assays for
myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-
ANCA were also included in the medical records. Patients
negative by antigen-specific assay but positive for ANCA by
IFA were considered to have MPO-ANCA or PR3-ANCA
when AAV was strongly suspected per clinical and labora-
tory features (12). All patients included in this study had
been followed up for at least three months or longer. Patients
had no serious medical conditions, such as coexisting
malignancies, serious infections, or chronic liver diseases
affecting the NFI value at diagnosis. In addition, they had
never received immunosuppressive drugs before the diag-
nosis. This study was approved by the Institutional Review
Board of Severance Hospital (4-2017-0673). The need for
patients’ written informed consent was waived, as this was a
retrospective study.
Exclusion of substantial liver diseases
Blood tests identified substantial liver diseases, liver
function, viral hepatitis A, B, and C, and imaging studies,
such as computed tomography or ultrasonography at diag-
nosis. In addition, they were confirmed by the 10th revised
International Classification of Diseases.
Clinical data at diagnosis and during follow-up
At diagnosis, age, sex, body mass index (BMI), and
smoking history were obtained. AAV subtypes, ANCA posi-
tivity, BVAS, and FFS were also collected as AAV-specific
indices. We assessed for chronic kidney disease (stages 3-5),
diabetes mellitus, hypertension, and interstitial pneumonia.
Erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP) levels were collected as acute-phase reactants, platelet
count, prothrombin time, serum albumin, alkaline phospha-
tase, aspartate aminotransferase, alanine aminotransferase,
and total bilirubin were also collected as liver-related vari-
ables. We also reviewed medications administered during
follow-up, including glucocorticoid, cyclophosphamide, ritu-
ximab, azathioprine, mycophenolate mofetil, tacrolimus, and
methotrexate.
Poor outcomes
All-cause mortality, relapse, and end-stage renal disease
(ESRD) were evaluated as poor AAV outcomes during
follow-up. The follow-up period was defined as the duration
between the diagnosis and the last visit for surviving
patients. Deceased patients were defined as the duration
between diagnosis and death. Patients who had relapse and
ESRDwere defined as the duration from diagnosis until relapse
or the renal replacement therapy initiation, respectively.
Equation for FCI and NFI
FCI and NFI were calculated using the following formulas:
FCI=(serum bilirubin alkaline phosphatase)/(platelet count
serum albumin) (8), and NFI=(serum bilirubin (alkaline
phosphatase)2)/(platelet count (serum albumin)2) (9).
Statistical analyses
All statistical analyses were conducted using the SPSS
software (version 23 for Windows; IBM Corp., Armonk,
NY, USA). Continuous variables were expressed as median
(interquartile range, IQR), and categorical variables were
expressed as numbers and percentages. Significant differ-
ences in categorical variables and continuous variables
between the two groups were analyzed using the Chi-square
and Fisher’s exact tests and the Mann-Whitney test. The
correlation coefficients between the two groups were obtained
using Pearson or Spearman correlation analyses. Comparing
the cumulative survival rates between the two groups was
performed using the Kaplan-Meier survival analysis with the
log-rank test. The multivariable Cox hazards model analysis
using statistical significance variables in the univariable Cox
hazards model analysis was conducted to obtain the hazard
ratios (HRs) during the considerable follow-up duration.
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The relative risk (RR) of A for B was analyzed using contin-
gency tables and the chi-square test. Statistical significance
was set at po0.05.
’ RESULTS
Characteristics of AAV patients at diagnosis
At the time of diagnosis, the patients’ median age was
59.0 years, and 32.5% were men. The median BMI was
22.2 kg/m2, and only seven patients had ever smoked but
were not current smokers. The most common AAV subtype
and detected ANCA type were MPA (55.2%) and MPO-
ANCA (or P-ANCA) (66.7%). The median BVAS and FFS
were 12.0 and 1.0, respectively. The most common comor-
bidity was hypertension (46.7%), followed by chronic kidney
disease (stage 3-5) (28.6%). The median ESR, CRP, NFI, and FCI
were 60.5 mm/hr, 13.2 mg/L, 0.61, and 0.032, respectively. The
median liver-related variables are presented in Table 1.
During the follow-up period, 21 patients (10%) died, 72
patients (34.3%) relapsed, and 38 patients (18.1%) had ESRD
due to AAV progression. The median follow-up duration
until each event was 34.5 months, 22.8 months, and 30.5
months, respectively. Glucocorticoids were administered to
91.4% of patients, and both cyclophosphamide (48.1%) and
azathioprine (47.6%) were most commonly used as induction
therapy and maintenance therapy (Table 1). Cyclophospha-
mide was administered intravenously in all patients, and
maintenance therapy continued for at least two years in most
patients.
Correlation of continuous variables at diagnosis
NFI and FCI tended to be correlated with AAV’s cross-
sectional activity based on BVAS but did not reach statistical
significance. Furthermore, neither NFI nor FCI was signifi-
cantly correlated with age, BMI, FFS, ESR, or CRP. In
addition, except for liver-related variables associated with
NFI and FCI, prothrombin time, aspartate aminotransferase,
and alanine aminotransferase were significantly correlated
with both NFI and FCI, as expected (Table 2).
Comparison of FCI and NFI at diagnosis based on
each poor outcome
Deceased AAV patients exhibited a higher NFI at diag-
nosis than survived AAV patients, but the difference was not
statistically significant (1.26 vs. 0.59, p=0.055). However,
there were no statistically significant NFI differences at diag-
nosis between AAV patients with relapse and those without
relapse, or AAV patients with ESRD and those without
ESRD. On the other hand, FCI at diagnosis did not differ
between the three groups classified according to all-cause
mortality, relapse, or ESRD occurrence (Figure 1).
Cut-offs of NFI and FCI at diagnosis for each poor
outcome
To obtain the cut-off values of NFI and FCI at diagnosis for
each poor outcome, we conducted the ROC curve analysis
but could not obtain the cut-offs. Instead, we arbitrarily
defined the NFI and FCI’s cut-off values as the lower limit of
the highest quartile at diagnosis: NFIX1.24 and FCIX0.057.
Comparison of cumulative survival rates
AAV patients with NFI at diagnosis X1.24 exhibited a
significantly lower cumulative patient survival rate than
those with NFI at diagnosis o1.24 (p=0.002). However, the
cumulative relapse-free and ESRD-free survival rates were
not different between AAV patients with NFI at diagnosis
X1.24 and those without. Meanwhile, FCI at diagnosis
Table 1 - Characteristics of AAV patients at diagnosis and during
follow-up (N=210).
AAV patients Values
At the time of diagnosis
Demographic data
Age (years) 59.0 (20.3)
Male gender (N, (%)) 68 (32.4)
Body mass index (kg/m2) 22.2 (4.4)
Smoking history (N, (%)) 7 (3.3)




ANCA positivity (N, (%))
MPO-ANCA (or P-ANCA) positivity 140 (66.7)
PR3-ANCA (or C-ANCA) positivity 35 (16.7)
Both ANCA positivity 9 (4.3)




Comorbidities at diagnosis (N, (%))
Chronic kidney disease (stage 3-5) 60 (28.6)
Diabetes mellitus 55 (26.2)
Hypertension 98 (46.7)
Interstitial lung disease 55 (26.2)
Acute-phase proteins
ESR (mm/hr) 60.5 (70.3)
CRP (mg/L) 13.2 (70.6)
Liver-related variables
Platelet count (x1,000/mm3) 304.5 (158.0)
Prothrombin time (INR) 1.0 (0.2)
Serum albumin (g/dL) 3.6 (1.2)
Alkaline phosphatase (IU/L) 70.5 (37.8)
Aspartate aminotransferase (IU/L) 18.0 (9.0)
Alanine aminotransferase (IU/L) 15.0 (15.0)
Total bilirubin (mg/dL) 0.5 (0.2)
NFI 0.61 (0.95)
FCI 0.032 (0.037)
During the follow-up period
Follow-up duration (months) 34.5 (64.6)
Poor outcomes during follow-up (N, (%))
All-cause mortality (N, (%)) 21 (10.0)
Follow-up duration based on all-cause mortality
(months)
34.5 (64.7)
Relapse (N, (%)) 72 (34.3)
Follow-up duration based on relapse (months) 22.8 (44.0)
ESRD (N, (%)) 38 (18.1)
Follow-up duration based on ESRD (months) 30.5 (69.4)





Mycophenolate mofetil 23 (11.0)
Tacrolimus 11 (5.2)
Methotrexate 19 (0.0)
Values are expressed as median (interquartile range [IQR]) or N (%).
AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic
antibody; MPA: microscopic polyangiitis; GPA: granulomatosis with poly-
angiitis; EGPA: eosinophilic GPA; MPO: myeloperoxidase; P: perinuclear;
PR3: proteinase 3; C: cytoplasmic; BVAS: Birmingham vasculitis activity
score; FFS: five-factor score; ESR: erythrocyte sedimentation rate; CRP:
C-reactive protein; NFI: novel fibrosis index; FCI: fibrosis cirrhosis index;
ESRD: end-stage renal disease.
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X0.057 could not predict any AAV’s poor outcome
(Figure 2).
Cox hazards model analysis for all-cause mortality
To clarify whether NFI at diagnosis X1.24 might be an
independent predictor of all-cause mortality during follow-
up, we conducted univariate and multivariate Cox hazards
model analysis using variables at diagnosis for all-cause
mortality. Liver-related variables were excluded from the
Cox analyses to minimize confounding effects on the
association between NFI and all-cause mortality. In the
univariate analysis, age, male sex, BVAS score, hypertension,
interstitial lung disease, CRP, and NFI at diagnosis X1.24,
were significantly associated with all-cause mortality. In
the multivariable analysis, age (HR 1.049, 95% confi-
dence interval [CI] 1.05, 1.095), BVAS (HR 1.082, 95% CI
1.010, 1.159), interstitial lung disease (HR 4.728, 95% CI
1.878, 11.901), and NFI at diagnosis X1.24 (HR 2.850,
95% CI 1.026, 7.910) were found to be independent pre-
dictors of all-cause mortality during follow-up in AAV
patients (Table 3).
Relative Risk of NFI at diagnosis X1.24 for all-cause
mortality
When we classified AAV patients into two groups based
on the calculated cut-off of NFI, 54 of 210 patients were
divided into the group with NFI at diagnosis X1.24. All-
cause mortality was identified more frequently in AAV
patients with NFI at diagnosis X1.24 than in those with NFI
at diagnosis o1.24 (20.4% vs. 6.3%, p=0.003). Furthermore,
AAV patients with NFI at diagnosis X1.24 had a signifi-
cantly higher risk for all-cause mortality than those with NFI
at diagnosis o1.24 (RR 3.735, 95% CI 1.468, 9.385) (Figure 3).
’ DISCUSSION
In this study, we investigated whether NFI, one of the
indices for liver fibrosis, might be associated with AAV’s
cross-sectional activity and could predict poor outcomes,
particularly all-cause mortality in immunosuppressive drug-
naïve patients with AAV. We found four valuable results as
follows: first, NFI could reflect the cross-sectional activity of
AAV based on BVAS or acute-phase reactants, including ESR
and CRP. Second, when the cut-off of NFI at diagnosis was
Table 2 - Correlation of continuous variables with either NFI or FCI at diagnosis in AAV patients.
Based on NFI Based on FCI
Variables Correlation coefficient (r) p-value Correlation coefficient (r) p-value
Age 0.061 0.380 0.063 0.366
BMI 0.046 0.511 0.046 0.503
BVAS 0.133 0.054 0.133 0.055
FFS 0.046 0.508 0.046 0.504
ESR 0.009 0.898 0.010 0.885
CRP -0.013 0.846 -0.005 0.937
Liver-related variables*
Prothrombin time (INR) 0.181 0.009 0.184 0.009
Aspartate aminotransferase (IU/L) 0.765 o0.001 0.770 o0.001
Alanine aminotransferase (IU/L) 0.635 o0.001 0.640 o0.001
NFI: novel fibrosis index; FCI: fibrosis cirrhosis index; AAV: ANCA-associated vasculitis; BMI: body mass index; BVAS: Birmingham vasculitis activity score;
FFS: five-factor score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
* Platelet count, serum albumin, alkaline phosphatase, and bilirubin, which are variables of the NFI and FCI equations, were not included in this table.
Figure 1 - Comparison of FCI and NFI at diagnosis based on each poor outcome. Among six conditions, only NFI at diagnosis in deceased
AAV patients tended to be increased compared to survived AAV patients, but it did not reach a statistical significance. NFI: novel
fibrosis index; ESRD: end-stage renal disease; FCI: fibrosis cirrhosis index.
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defined as the lower limit of the higher quartile, AAV
patients with NFI at diagnosis X1.24 exhibited a signifi-
cantly lower cumulative patient survival rate than those with
NFI at diagnosis o1.24. Third, in the multivariable Cox
hazards model analysis, NFI at diagnosis X1.24 could
independently predict all-cause mortality during follow-up
together with age, BVAS, and interstitial lung disease at
diagnosis. Lastly, AAV patients with NFI at diagnosis X1.24
had a significantly higher risk for all-cause mortality than
those with NFI at diagnosis o1.24 (RR 3.735).
When we assessed the frequency of affected organs based
on the nine items of the BVAS in our study population, the
most commonly affected area was renal manifestation
(60.0%), followed by pulmonary (57.1%), and ear nose throat
(ENT) (44.8%). We wondered which specific organ involve-
ment was associated with NFI and found that only the ENT
manifestation frequency among the nine manifestations
exhibited a significant difference in NFI. Ninety-four AAV
patients with ENT manifestation exhibited a statistically
significantly higher median NFI than 116 AAV patients
without ENT manifestation (0.74 vs. 0.50, p=0.024).
Although it has been controversial whether sinusitis might
be a typical surrogate marker for GPA, sinusitis is the
most common symptom of ENT involvement in AAV (13).
We conducted a literature review on the association of
sinusitis with the four variables that compose an NFI
formula and found a previous study reported that serum
albumin was significantly lower in patients with chronic
rhinosinusitis than those without (14). However, in this
study, serum albumin levels did not differ between AAV
patients with and without ENT manifestations. In addi-
tion, since serum albumin is more clinically linked to
renal manifestation. It is difficult to explain the diffe-
rence in NFI between AAV patients with and those without
ENT manifestation by the results of this previous study
alone.
In this study, when the ROC curve dependent variable was
designated as all-cause mortality or ESRD, statistical
Figure 2 - Comparison of the cumulative survival rates. Among six conditions, it was found that only AAV patients with NFI at diagnosis
X1.24 exhibited a significantly lower cumulative patients’ survival rate than those without. NFI: novel fibrosis index; ESRD: end-stage
renal disease; FCI: fibrosis cirrhosis index.
Table 3 - Cox hazards model analysis of variables at diagnosis for all-cause mortality during follow-up in AAV patients.
Variables
Univariable Multivariable
HR 95% CI p-value HR 95% CI p-value
Age 1.060 1.019, 1.104 0.004 1.049 1.005, 1.095 0.029
Body mass index 1.115 0.962, 1.293 0.147
Male gender 2.410 1.021, 5.690 0.045 2.289 0.899, 5.830 0.082
Smoking history 1.964 0.262, 14.734 0.512
MPO-ANCA (or P-ANCA) positivity 1.784 0.682, 4.664 0.238
PR3-ANCA (or C-ANCA) positivity 1.036 0.348, 3.088 0.949
BVAS 1.081 1.002, 1.143 0.007 1.082 1.010, 1.159 0.024
Chronic kidney disease (stage 3-5) 1.985 0.833, 4.733 0.122
Diabetes mellitus 1.015 0.393, 2.619 0.976
Hypertension 3.132 1.145, 8.566 0.026 1.414 0.471, 4.241 0.536
Interstitial lung disease 5.614 2.307, 13.663 o0.001 4.728 1.878, 11.901 0.001
ESR 1.009 0.998, 1.020 0.108
CRP 1.007 1.001, 1.014 0.022 0.999 0.991, 1.007 0.768
NFI at diagnosis X1.24 3.627 1.538, 8.556 0.003 2.850 1.026, 7.910 0.044
AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; MPO: myeloperoxidase; P: perinuclear; PR3: proteinase 3; C: cytoplasmic;
BVAS: Birmingham vasculitis activity score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; NFI: novel fibrosis index.
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significance was not obtained. There are cases where there is
no or low statistical significance when calculating the cut-off
using the ROC curve because the follow-up duration based
on all-cause mortality or ESRD occurrence was not con-
sidered. Conversely, the Kaplan-Meier survival analysis used
to evaluate the predictive indicator potential requires follow-
up duration based on each poor prognosis. On the other
hand, in the case of failure to obtain the cut-off using the
ROC curve, the highest or the lowest tertile or quartile is
occasionally used to obtain a statistically significant cut-off.
We also designated the NFI and FCI’s highest quartiles as
cut-off values for all-cause mortality and ESRD occurrence in
this study. They exhibited statistical significance or a trend of
significance in the Kaplan-Meier analysis.
Despite no statistical significance, NFI and FCI areas at
diagnosis for all-cause mortality and ESRD using the ROC
curve were qualitatively compared. First, in the ROC curve
analysis based on all-cause mortality, NFI at diagnosis
showed a wider area under the curve than FCI at diagnosis.
Moreover, in the ROC curve analysis based on ESRD, NFI at
diagnosis also showed a wider area under the curve than FCI
at diagnosis (Appendix - Supplementary Figure 1). There-
fore, although the statistical significance was low and the
follow-up period was not taken into account, NFI at diag-
nosis tended to better predict the occurrence of all-cause
mortality and ESRD during follow-up than FCI at diagnosis.
The exact mechanism of how NFI at diagnosis indepen-
dently predicts all-cause mortality during AAV patients’
follow-up is unclear. However, we made some assumptions.
Hypoalbuminemia is a well-known major risk factor for poor
prognosis, including all-cause mortality and ESRD occur-
rence in AAV patients (15). Since serum albumin is in the NFI
formula’s denominator, NFI and serum albumin theoretically
show an inverse correlation. Therefore, it can be inferred that
the smaller the albumin level, the higher the NFI. The highest
NFI quartile at diagnosis indicates a lower level of serum
albumin could predict all-cause mortality in AAV patients.
The Pearson correlation analysis performed in our study did
not reach statistical significance but showed a tendency
toward a negative correlation (r=-0.119, p=0.084). Using the
Spearman correlation analysis, serum albumin levels were
significantly and inversely correlated with NFI (rho=-0.322,
po0.001). These results support our assumption that NFI can
predict all-cause mortality through serum albumin levels.
In terms of platelet count, there have been studies
demonstrating that platelet counts reflect AAV’s inflammatory
burden, correlate with BVAS, and may predict poor outcomes
in AAV patients (10,16). Since platelet count is also in the
denominator of NFI’s formula, theoretically, the larger the
platelet counts, the smaller the NFI. However, the results of
our study disagreed. When we focus on two variables in the
denominator, serum albumin can be considered to have a
direct effect on NFI’s increase more than platelet count.
Therefore, we concluded that the highest quartile of NFI at
diagnosis made a more direct contribution to predicting all-
cause mortality through reduced serum albumin, which could
reflect the high degree of inflammation and malnutrition.
In the Kaplan-Meier survival analysis, the cumulative ESRD-
free survival rate in AAV patients with NFI at diagnosis X1.24
was lower than that in AAV patients with NFI at diagnosis
o1.24 (p=0.072). However, the difference was not statistically
significant. This result may suggest that analyzing a larger
number of patients can yield statistically significant results.
How can NFI at diagnosis, which belongs to the highest
quartile, tend to predict ESRD during follow-up in AAV
patients? In terms of comorbidity of chronic kidney disease,
AAV patients with chronic kidney disease at diagnosis showed
higher NFI than those without (0.86 vs. 0.55, p=0.060). There-
fore, NFI can be assumed to reflect the accompanying chronic
kidney disease at diagnosis, which could potentially predict
ESRD occurrence in AAV patients (17).
In terms of serum albumin, high NFI means reduced
serum albumin at diagnosis, as described above. Reduced
serum albumin, in turn, is associated with renal manifestation
Figure 3 - Relative Risk for all-cause mortality. AAV patients with NFI at diagnosis X1.24 had a significantly higher risk for all-cause
mortality than those with NFI at diagnosis o1.24 (RR 3.735). NFI: novel fibrosis index; RR: relative risk; CI: confidence interval.
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and increased BVAS and is another crucial risk factor for
ESRD (3,18). Using the univariable Cox hazards model
analysis, serum albumin level at diagnosis was significantly
associated with ESRD during the follow-up period based on
ESRD occurrence (HR 0.585, 95% CI 0384, 0.890). These results
support our assumption that NFI can predict ESRD through
serum albumin levels.
NFI was originally a liver fibrosis index (19). Nevertheless,
how can it predict ESRD? Although the cells involved in liver
fibrosis and renal fibrosis are different, biological factors,
such as cytokines and chemokines that ultimately induce and
promote collagen deposition in organs, may share common
signal pathways in the two different fibrosis processes (9,20).
Therefore, although it is difficult to explain the exact
mechanism, it is expected that the liver fibrosis index can
predict the process of renal fibrosis to some extent.
To the best of our knowledge, this is the first study to
demonstrate that NFI at diagnosis could independently
predict all-cause mortality in immunosuppressive drug-
naïve AAV patients without chronic liver diseases. The
discovery of a new predictor of all-cause mortality in AAV
patients is an essential advantage of our research. In
addition, our study was conducted in a single institution,
which may be a drawback. Still, it is also an advantage in
that chronic liver diseases at the time of diagnosis and during
the follow-up period were strictly excluded from this study.
Our study has several limitations. Although chronic liver
diseases were excluded from this study, there was no
information on liver fibrosis examined by transient elasto-
graphy or ultrasonography in high NFI patients. The
disadvantage is that there is no serial information on liver
fibrosis in deceased AAV patients. Due to a retrospective
single institutional study’s limitations, there is a possibility of
selection bias, and missing data among clinical data could
not be completely excluded. Future prospective longitudinal
studies with a larger sample of AAV patients and serial
information regarding the liver fibrosis presence measured
by transient elastography will validate and support our
research and provide dynamic data on NFI in AAV patients.
’ CONCLUSION
Our study demonstrated that NFI at diagnosis was not asso-
ciated with the cross-sectional BVAS. In contrast, the highest
quartile of NFI at diagnosis could independently predict all-
cause mortality during follow-up in immunosuppressive drug-
naïve AAV patients without substantial liver diseases.
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’ APPENDIX
Supplementary Figure 1 - Comparison of the areas under the curve between NFI and FCI in the ROC curve analysis based on all-cause
mortality and ESRD occurrence. NFI: novel fibrosis index; FCI: fibrosis cirrhosis index; ROC: Receiver Operating Characteristic; ESRD: end-
stage renal disease.
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